Tuesday, October 6, 2020

The BNT162b2 vaccine candidate is based on BioNTech’s proprietary #mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities; Contains PEG - PEG’s stealth properties—its ability to mask and protect the carrier from the body’s normal defenses against foreign substances (No, Thank You.)

https://finance.yahoo.com/news/pfizer-biontech-covid-19-candidate-124906426.html

Pfizer-BioNTech Covid-19 Candidate Fast-Tracked By EU Agency; Shares Rise

The BNT162b2 vaccine candidate is based on BioNTech’s proprietary #mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. It encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S), which is a target of virus neutralizing antibodies.

#SARSCoV2 #BioNTech #Pfizer #BNT162b2

+++

https://childrenshealthdefense.org/news/a-dangerous-inactive-ingredient/

#PEG and Covid-19 Vaccines

There are at least three fast-tracked vaccines being produced and tested at this time, obviously meant for widespread use, some even arguing mandatory use, which contain PEG

Moderna’s mRNA1273

BioNTech/Pfizer’s BNT162b1 and b2

These mRNA vaccines trick your cells into producing Covid-19 proteins—pieces of the virus which are non-infectious.

These proteins then elicit an immune response to fight the real virus.

They use a pegylated Lipid Nanoparticle (LNP) as the delivery mechanism for the mRNA.

Think of the LNP as a miniscule (less than 100 billionth of a meter) bubble containing the mRNA.

This “bubble” is coated with PEG (DSPE MPEG2000 in Moderna’s case) to stabilize the carrier and assist it in getting to and into the target cells.

PEG assists with the “getting to” portion of the journey by preventing the bubble from breaking down before it reaches its target.

That is what some call PEG’s stealth properties—its ability to mask and protect the carrier from the body’s normal defenses against foreign substances.

[Thank you. I will pass on this one.]

 

No comments:

Post a Comment